Prospective study of Docetaxel combined with Bevacizumab in advanced or recurrent non-squamous non-small cell lung cancer patients unfit for platinum-doublet chemotherapy and exploratory biomarker analysis for predicting the effect with antiangiogenic therapy.(OLCAS-001)
Not Applicable
- Conditions
- on-squamous non-small cell lung cancer
- Registration Number
- JPRN-UMIN000009263
- Lead Sponsor
- Oita University Faculty of Medicine, Department of Medical Oncology & Hematology
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Not provided
Exclusion Criteria
1) with uncontrollable co-morbidities 2)with episode of hemoptysis 3)clinically unfit for bevacizumab containing chemotherapy 4)with severe allergy of the medication 5)with ineligible conditions judged by the attending physician
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Progression free survival
- Secondary Outcome Measures
Name Time Method